Mesoblast Limited (AU:MSB) has released an update.
Mesoblast Limited, an Australian biotechnology firm, has successfully filed its annual report for the fiscal year ending June 30, 2024, with the U.S. Securities and Exchange Commission. The company, which is listed on the NASDAQ Global Select Market under the symbol MESO, reported a total of 1,141,784,114 Ordinary Shares outstanding at the close of the reporting period. Mesoblast has been in compliance with all SEC filing requirements over the past year and is classified as a non-accelerated filer under Exchange Act rules.
For further insights into AU:MSB stock, check out TipRanks’ Stock Analysis page.
